Alnylam Pharmaceuticals Inc Q2 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Okay. Great. So back to AMVUTTRA and the start forms and the 2/3 switches from ONPATTRO. What's the profile of initial patients that are switching from ONPATTRO? Are you getting a sense if it's more patient- or physician-driven? Do they stay on ONPATTRO up until they get AMVUTTRA? If that takes some time? And how do you expect that split between new and switches to shift over the next couple of quarters?

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : I guess not an ATTR question, but on the pipeline for lumasiran and recurrent renal stones, I guess maybe just with the Phase III finishing enrolling here this year, thinking about Phase II data next year. I mean, how should we think about what you're looking to see here? It's obviously a much broader population. I guess, what could we learn in terms of the relationship between oxalate reduction and reduction in stone formation in this broader population, and your confidence in the biology there? And then, I guess, thinking about sort of the regulatory pathway from there, like what a potential Phase III could look like? And any types of like patient segmentation in terms of accessing this much larger population.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just on cemdisiran and the IgA nephropathy data. Can you sort of discuss where you see like the complement inhibitor methodology sitting in the lines of therapy and I guess, how it relates to the data that we've seen from the endothelin receptor-1 antagonist. And I guess, is that a key consideration for Regeneron and how they would potentially design a pivotal study and the types of patients that you would enroll in that pivotal study?